Trazodone for Insomnia Treatment

Evidence Against Trazodone for Insomnia

The American Academy of Sleep Medicine recommends against using trazodone for both sleep onset and sleep maintenance insomnia, based on trials of 50 mg doses, with a "WEAK" rating indicating low evidence quality 1, 2
Clinical trials showed only modest improvements in sleep parameters compared to placebo, with no significant improvement in subjective sleep quality, despite trazodone's widespread off-label use for insomnia 2

The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia, including components such as cognitive therapy, stimulus control therapy, and sleep restriction therapy 3, 2
For sleep onset and maintenance insomnia, recommended medications include eszopiclone (2-3 mg) 1, 2, zolpidem (10 mg) 1, 2, and temazepam (15 mg) 1
For sleep onset insomnia only, recommended medications include zaleplon (10 mg) 1, 2, ramelteon (8 mg) 1, 2, and triazolam (0.25 mg) 1
For sleep maintenance insomnia only, recommended medications include suvorexant 1, 2 and doxepin (3-6 mg) 1, 2

All hypnotic medications should be used at the lowest effective dose and for the shortest possible duration, with regular follow-up to assess medication effectiveness, side effects, and the ongoing need for pharmacotherapy 3, 2
Over-the-counter sleep aids and herbal supplements are not recommended for chronic insomnia due to lack of efficacy and safety data 1, 3

The American Academy of Sleep Medicine notes that antidepressant efficacy for insomnia "is not well established" when used at low doses, and combining two antidepressants is not recommended 4

The American Academy of Sleep Medicine suggests that combining two sedating antidepressants carries significant risks, including serotonin syndrome, excessive sedation, and QTc prolongation, and recommends optimizing doxepin dosing first, with a guideline-recommended dose of 3-6mg for insomnia 4
If monotherapy options are exhausted, consider combining low-dose doxepin (3-6mg) with a benzodiazepine receptor agonist, which has more clinical experience supporting "general safety and efficacy" 4